A single view of all the companies in the same space to infer if the stock is undervalued, overvalued or priced right. This would be one way to analyze a longer terms investment in a particular sector.
| Company | Market Cap | Income | Sales | P/E | P/B | Cash/Share | Dividend | Dividend Yield | Price To Cash Ratio | Debt to Equity Ratio | ROE | ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progenity, Inc. | 193,910,000 | -178,500,000 | 1,200,000 | 0.00 | 0.00 | 0.45 | - | - | 2.19 | 0.00 | 187.80% | -217.50% |
| Aytu BioPharma, Inc. | 23,730,000 | -83,900,000 | 82,000,000 | 0.00 | 0.16 | 0.97 | - | - | 0.67 | 0.22 | -67.40% | -33.90% |
| BiondVax Pharmaceuticals Ltd. | 28,120,000 | -12,300,000 | 0 | 0.00 | 2.70 | 0.80 | - | - | 1.68 | 2.99 | -267.80% | -44.00% |
| Graybug Vision, Inc. | 23,660,000 | -35,800,000 | 0 | 0.00 | 0.35 | 2.91 | - | - | 0.37 | 0.00 | -47.70% | -44.90% |
| Kaleido Biosciences, Inc. | 2,960,000 | 0 | 850,000 | 0.00 | 0.10 | 0.00 | - | - | 0.00 | 0.00 | - | - |
| Palisade Bio, Inc. | 15,640,000 | -26,600,000 | 0 | 0.00 | 1.60 | 0.58 | - | - | 1.49 | 0.01 | - | -202.20% |
| Passage Bio, Inc. | 142,250,000 | -185,400,000 | 0 | 0.00 | 0.42 | 5.53 | - | - | 0.45 | 0.00 | -48.60% | -44.90% |